Efraim Rosenberg

Dr. Efraim Rosenberg

Pathology - DNA diagnostics, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Noord-Holland, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SLSuzanne Leijen
Suzanne Leijen
RGRobin M.J.M. van Geel
Robin M.J.M. van Geel
GSGabe S. Sonke
Gabe S. Sonke
DJDaphne de Jong
Daphne de Jong
Efraim RosenbergEfraim Rosenberg
Efraim Rosenberg
JSJan H.M. Schellens
Jan H.M. Schellens
Purpose: AZD1775 is a first-in-class, potent, and selective inhibitor of WEE1 with proof of chemopotentiation in p53-deficient tumors in preclinical models. In a phase I study, the maximum tolerated dose of AZD1775 in combination with carboplatin demonstrated target engagement. We conducted a proof-of-principle phase II study in patients with p53 tumor suppressor gene ( TP53)–mutated ovarian cancer refractory or resistant (< 3 months) to first-line platinum-based therapy to determine overall response rate, progression-free and overall survival, pharmacokinetics, and modulation of phosphorylated cyclin-dependent kinase (CDK1) in skin biopsies. Patients and Methods: Patients were treated with carboplatin (area under the curve, 5 mg/mL⋅min) combined with AZD1775 225 mg orally twice daily over 2.5 days every 21-day cycle until disease progression. Results: AZD1775 plus carboplatin demonstrated manageable toxicity; fatigue (87%), nausea (78%), thrombocytopenia (70%), diarrhea (70%), and vomiting (48%) were the most common adverse events. The most frequent grade 3 or 4 adverse events were thrombocytopenia (48%) and neutropenia (37%). Of 24 patients enrolled, 21 patients were evaluable for efficacy end points. The overall response rate was 43% (95% CI, 22% to 66%), including one patient (5%) with a prolonged complete response. Median progression-free and overall survival times were 5.3 months (95% CI, 2.3 to 9.0 months) and 12.6 months (95% CI, 4.9 to 19.7), respectively, with two patients with ongoing response for more than 31 and 42 months at data cutoff. Conclusion: To our knowledge, this is the first report providing clinical proof that AZD1775 enhances carboplatin efficacy in TP53-mutated tumors. The encouraging antitumor activity observed in patients with TP53-mutated ovarian cancer who were refractory or resistant (< 3 months) to first-line therapy warrants further development.

1 July 2004 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
Efraim RosenbergEfraim Rosenberg
Efraim Rosenberg
LALigia S. Almeida
Ligia S. Almeida
TKTjitske Kleefstra
Tjitske Kleefstra
RDRose S. Degrauw
Rose S. Degrauw
HYHelger G. Yntema
Helger G. Yntema
GSGajja S. Salomons
Gajja S. Salomons

13 January 2009 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RGRenata C. Gallagher
Renata C. Gallagher
JHJohan L. K. Van Hove
Johan L. K. Van Hove
GSGunter Scharer
Gunter Scharer
KHKeith Hyland
Keith Hyland
BPBarbara Plecko
Barbara Plecko
CJCornelis Jakobs
Cornelis Jakobs

30 March 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
VJVincent M.T. de Jong
Vincent M.T. de Jong
YWYuwei Wang
Yuwei Wang
NHNatalie D. ter Hoeve
Natalie D. ter Hoeve
MOMark Opdam
Mark Opdam
NSNikolas Stathonikos
Nikolas Stathonikos
SLSabine C. Linn
Sabine C. Linn
PURPOSE: Triple-negative breast cancer (TNBC) is considered aggressive, and therefore, virtually all young patients with TNBC receive (neo)adjuvant chemotherapy. Increased stromal tumor-infiltrating lymphocytes (sTILs) have been associated with a favorable prognosis in TNBC. However, whether this association holds for patients who are node-negative (N0), young (< 40 years), and chemotherapy-naïve, and thus can be used for chemotherapy de-escalation strategies, is unknown. METHODS: We selected all patients with N0 TNBC diagnosed between 1989 and 2000 from a Dutch population–based registry. Patients were age < 40 years at diagnosis and had not received (neo)adjuvant systemic therapy, as was standard practice at the time. Formalin-fixed paraffin-embedded blocks were retrieved (PALGA: Dutch Pathology Registry), and a pathology review including sTILs was performed. Patients were categorized according to sTILs (< 30%, 30%-75%, and ≥ 75%). Multivariable Cox regression was performed for overall survival, with or without sTILs as a covariate. Cumulative incidence of distant metastasis or death was analyzed in a competing risk model, with second primary tumors as competing risk. RESULTS: sTILs were scored for 441 patients. High sTILs (≥ 75%; 21%) translated into an excellent prognosis with a 15-year cumulative incidence of a distant metastasis or death of only 2.1% (95% CI, 0 to 5.0), whereas low sTILs (< 30%; 52%) had an unfavorable prognosis with a 15-year cumulative incidence of a distant metastasis or death of 38.4% (32.1 to 44.6). In addition, every 10% increment of sTILs decreased the risk of death by 19% (adjusted hazard ratio: 0.81; 95% CI, 0.76 to 0.87), which are an independent predictor adding prognostic information to standard clinicopathologic variables (χ2 = 46.7, P < .001). CONCLUSION: Chemotherapy-naïve, young patients with N0 TNBC with high sTILs (≥ 75%) have an excellent long-term prognosis. Therefore, sTILs should be considered for prospective clinical trials investigating (neo)adjuvant chemotherapy de-escalation strategies.

26 April 2006 in Human Genetics
Verified
Journal Article
Closed access
PDF file
ACAmy J. Clark
Amy J. Clark
Efraim RosenbergEfraim Rosenberg
Efraim Rosenberg
LALigia S. Almeida
Ligia S. Almeida
TWTim C. Wood
Tim C. Wood
CJCornelis Jakobs
Cornelis Jakobs
GSGajja S. Salomons
Gajja S. Salomons

4 May 2001 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
PTPeter E.M. Taschner
Peter E.M. Taschner
JJJeroen C. Jansen
Jeroen C. Jansen
BBBora E. Baysal
Bora E. Baysal
ABAnne Bosch
Anne Bosch
Efraim RosenbergEfraim Rosenberg
Efraim Rosenberg
PDPeter Devilee
Peter Devilee